Serum concentrations of gabapentin in cats with chronic kidney disease.

J Feline Med Surg. December 2022;24(12):1260 - 1266.

Jessica M Quimby¹, Sarah K Lorbach², Ashlie Saffire³, Amanda Kennedy⁴, Luke A Wittenburg⁵, Turi K Aarnes⁶, Karina J Creighton⁷, Sarah E Jones⁸, Rene E Paschall⁹, Emily M King¹⁰, Clara E Bruner¹¹, Jessica N Wallinger¹², Karen A van Haaften¹³

¹ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ² Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ³ Cats Only Veterinary Clinic, Columbus, OH, USA.; ⁴ Cats Only Veterinary Clinic, Columbus, OH, USA.; ⁵ Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California - Davis, CA, USA.; ⁶ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ⁷ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ⁸ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ⁹ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ¹⁰ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ¹¹ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ¹² Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.; ¹³ British Columbia SPCA, Vancouver, BC, Canada.

Abstract

OBJECTIVES:The purpose of this study was to assess serum concentrations of gabapentin in cats with chronic kidney disease (CKD) vs clinically healthy cats.

METHODS:Five healthy cats were enrolled in a pharmacokinetic study. A single 20 mg/kg dose of gabapentin was administered orally and blood was obtained at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24 and 36 h via a jugular catheter. Serum gabapentin concentrations were measured using liquid chromatography coupled to tandem mass spectrometry. Non-compartmental pharmacokinetic analysis was performed. The same five healthy cats plus 25 cats with stable International Renal Interest Society stage 2 (n = 14) and 3 (n = 11) CKD were enrolled in a limited sampling study. Cats in both groups received a single 10 mg/kg dose of gabapentin, and serum gabapentin concentrations and compliance scores were obtained 3 and 8 h post-administration.

RESULTS:Cats with CKD had significantly higher dose-normalized serum gabapentin concentrations than normal cats at 3 h (P = 0.0012 CKD vs normal 10 mg/kg; P = 0.008 CKD vs normal 20 mg/kg) and 8 h (P <0.0001 CKD vs normal 10 mg/kg; P <0.0001 CKD vs normal 20 mg/kg). Both 3 and 8 h dose-normalized serum gabapentin concentrations were significantly correlated with serum creatinine (3 h: P = 0.03, r = 0.39; 8 h: P = 0.001, r = 0.57) and symmetric dimethylarginine (3 h: P = 0.03, r = 0.41; 8 h: P = 0.007, r = 0.48). There was a significant correlation between 3 h serum gabapentin concentrations and compliance scores (P = 0.0002, r = 0.68).

CONCLUSIONS AND RELEVANCE:Cats with CKD that received 10 mg/kg of gabapentin had significantly higher dose-normalized serum concentrations than normal cats that received 20 mg/kg, supporting the need to dose-reduce in this patient population.

Keywords

Anxiety; elimination rate; half-life; renal failure; stress;

Article Tools:

Medline

Email to me

Grants:

K01 OD026526 OD NIH HHS

Archives Highlights:

A public health campaign to increase awareness of the risk of dog bites in South Australia.
Over one third (36-37%) of dog owners and 25-29% of non-dog owners had been previously bitten by a dog, although most did not require medical attention. Approximately 70% of dog owners believed it was safe for strangers to approach their dog, 34-37% allowed children or other people to pat their dog without permission, and less than half separated their dog from visitors or delivery people. In contrast, few of the non-dog owners allowed their children to pat a dog without the owner's permission and only 2% allowed them to play with dogs without supervision.

Clinical characterization of a novel episodic ataxia in young working Cocker Spaniels.
The mean age at clinical onset was 4 months. Signs were acute and included episodic body swaying, titubation, cerebellar ataxia, wide-base stance, and hypermetria, all while mentation remained unaltered. Duration of episodes ranged from 30 minutes up to 24 hours, and their frequency varied from weekly to once every 5 months.

National survey reveals elastic price sensitivity for select equine veterinary services.
Willingness-to-pay questions were presented with a payment card approach and addressed 3 common services: annual spring vaccinations, lameness examinations, and emergency colic surgeries. In a payment card approach, respondents choose from among preselected values. Respondents were asked to choose the maximum amount they would be willing to pay for each service.

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.
On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority. By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54%, and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 µmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin).

Case series of maggot debridement therapy demonstrates safety and efficacy for treating problematic wounds in cats and dogs in Mexico.
Treatment was administered by applying 8-10 larvae per square cm surface area directly on the wound bed and covering the wound with a sterile polyester mesh, sutured to the skin. These were left on the wound for cycles of approximately 48 hours (24-72 hours); the cycles were repeated if more than 20% necrotic tissue remained after treatment. Review of these cases revealed that 80% of treated wounds achieved 100% debridement within 48-96 hours of treatment.